AAI-CSI joint Symposium in the 2014 AAI annual meeting
Source：CSI
2014-05-20
The 2014 AAI (the American Association of Immunologists) annual meeting has been held on May 2-6, 2014, at David L. Lawrence Convention Center, Pittsburgh, Pennsylvania, USA. More than 2000 participants from USA and other countries have attended this meeting. As usual, there were guest society symposia and the AAI-CSI (Chinese Society for Immunology) joint symposium was held on May 4 at room 319, and it is the 7th time since CSI has been invited to host a guest society symposium in AAI annual meeting. Prof. Xuetao Cao, the president of CSI, and Prof. Olivera J. Finn from University of Pittsburgh School of Medicine co-chaired this symposium.
The topic of this symposium is “Cancer Immunotherapy Targeting Chronic Inflammation and Immunosuppression”, around which four professors from China gave speech respectively: Prof. Xuetao Cao gave the key note speech titled of “Overview of tumor immunology and immunotherapy in China”, introducing the rapid development of tumor immunology in China and the new findings on type I IFN and hepatocarcinoma from his lab; Prof. Limin Zheng from Sun Yat-sen University made the speech titled of “Macrophage plasticity in distinct microenvironments of human tumor”, discussing the plasticity of macrophages in human hepatocelluar carcinoma tissue and its effect on tumor development; Prof. Xiyun Yan from Institute of Biophysics, Chinese Academy of Science made the speech titled of “Targeting CD146 for cancer immunotherapy”, talking about the searching of new target for anti-tumor antibody preparation; and Prof Bo Huang from Chinese Academy of Medical Sciences made the speech titled of “Microparticles in cancer immunotherapy”, introducing the new anti-tumor therapy by tumor cell-derived microparticles.
The exciting research achievements by Chinese immunologists on the tumor immunology attracted so many participants than expected that some of them had to stand during the whole meeting because there were no enough seats for all participants. During the symposium many questions were asked and discussed, both speakers and attendees enjoyed sharing opinions on the hot topics on immunology. As always, the CSI symposium in the AAI annual meeting is not only a good opportunity to reflect the rapid development of Chinese immunology directly, but also to show the confidence of Chinese immune researchers all around the world.
The topic of this symposium is “Cancer Immunotherapy Targeting Chronic Inflammation and Immunosuppression”, around which four professors from China gave speech respectively: Prof. Xuetao Cao gave the key note speech titled of “Overview of tumor immunology and immunotherapy in China”, introducing the rapid development of tumor immunology in China and the new findings on type I IFN and hepatocarcinoma from his lab; Prof. Limin Zheng from Sun Yat-sen University made the speech titled of “Macrophage plasticity in distinct microenvironments of human tumor”, discussing the plasticity of macrophages in human hepatocelluar carcinoma tissue and its effect on tumor development; Prof. Xiyun Yan from Institute of Biophysics, Chinese Academy of Science made the speech titled of “Targeting CD146 for cancer immunotherapy”, talking about the searching of new target for anti-tumor antibody preparation; and Prof Bo Huang from Chinese Academy of Medical Sciences made the speech titled of “Microparticles in cancer immunotherapy”, introducing the new anti-tumor therapy by tumor cell-derived microparticles.
The exciting research achievements by Chinese immunologists on the tumor immunology attracted so many participants than expected that some of them had to stand during the whole meeting because there were no enough seats for all participants. During the symposium many questions were asked and discussed, both speakers and attendees enjoyed sharing opinions on the hot topics on immunology. As always, the CSI symposium in the AAI annual meeting is not only a good opportunity to reflect the rapid development of Chinese immunology directly, but also to show the confidence of Chinese immune researchers all around the world.
